• Elevance Health Q2 2026 shareholders’ net income fell 16.1% to $1.46 billion; diluted EPS dropped 13.1% to $6.71.
• Operating revenue rose 0.8% to $49.8 billion; operating gain slid 27.3% to $1.76 billion, cutting operating margin by 1.4 percentage points to 3.5%.
• Benefit expense ratio widened 0.8 percentage points to 89.7%; operating expense ratio increased 1 percentage point to 11.1%.
• Health Benefits operating gain sank 42.6% to $896 million; Carelon operating revenue climbed 6% to $19.2 billion, with operating gain steady at $900 million.
• Raised full-year adjusted EPS guidance to at least $27.00; CEO Gail Boudreaux cited stronger execution, targeted investments, and a goal of at least 12% adjusted EPS growth in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elevance Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260714657695) on July 15, 2026, and is solely responsible for the information contained therein.